JP2022515721A - ＦＡＰαに特異的な二環式ペプチドリガンド - Google Patents

ＦＡＰαに特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2022515721A
JP2022515721A JP2021534207A JP2021534207A JP2022515721A JP 2022515721 A JP2022515721 A JP 2022515721A JP 2021534207 A JP2021534207 A JP 2021534207A JP 2021534207 A JP2021534207 A JP 2021534207A JP 2022515721 A JP2022515721 A JP 2022515721A
Authority
JP
Japan
Prior art keywords
peptide ligand
acid
peptide
fapα
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534207A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020120979A5 (enExample
Inventor
シェン リューホン
ステイス キャサリン
ウォーカー エドワード
Original Assignee
バイスクルアールディー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイスクルアールディー・リミテッド filed Critical バイスクルアールディー・リミテッド
Publication of JP2022515721A publication Critical patent/JP2022515721A/ja
Publication of JPWO2020120979A5 publication Critical patent/JPWO2020120979A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021534207A 2018-12-13 2019-12-13 ＦＡＰαに特異的な二環式ペプチドリガンド Pending JP2022515721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1820320.8 2018-12-13
GBGB1820320.8A GB201820320D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for FAPalpha
PCT/GB2019/053535 WO2020120979A1 (en) 2018-12-13 2019-12-13 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPα

Publications (2)

Publication Number Publication Date
JP2022515721A true JP2022515721A (ja) 2022-02-22
JPWO2020120979A5 JPWO2020120979A5 (enExample) 2022-12-19

Family

ID=65147028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534207A Pending JP2022515721A (ja) 2018-12-13 2019-12-13 ＦＡＰαに特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220008545A1 (enExample)
EP (1) EP3894005A1 (enExample)
JP (1) JP2022515721A (enExample)
CN (1) CN113507961A (enExample)
GB (1) GB201820320D0 (enExample)
WO (1) WO2020120979A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
CN111118063B (zh) * 2019-12-05 2023-04-18 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502825A (ja) * 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2018197893A1 (en) * 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293311A1 (en) * 2002-09-18 2004-04-23 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
CN108383893A (zh) * 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502825A (ja) * 2014-10-29 2018-02-01 バイサイクル・セラピューティクス・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2018197893A1 (en) * 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof

Also Published As

Publication number Publication date
CN113507961A (zh) 2021-10-15
EP3894005A1 (en) 2021-10-20
WO2020120979A1 (en) 2020-06-18
GB201820320D0 (en) 2019-01-30
US20220008545A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
JP2022518695A (ja) Ｃａｉｘに特異的な二環式ペプチドリガンド
JP2022514255A (ja) Ｐｓｍａに特異的な二環式ペプチドリガンド
JP7682852B2 (ja) ＥｐｈＡ２に特異的な二環式ペプチドリガンド
JP2022514618A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
EP4053145B1 (en) Bicyclic peptide ligands specific for epha2
JP2022517442A (ja) Ｃａｉｘに特異的な二環式ペプチドリガンド
JP7460523B2 (ja) ＥｐｈＡ２に特異的な二環ペプチドリガンド
JP2022518210A (ja) インテグリンαｖβ３に特異的な二環式ペプチドリガンド
JP2022514687A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP2022517698A (ja) インテグリンαｖβ３に特異的な二環式ペプチドリガンド
JP2022517040A (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
JP2022512478A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
JP2022513223A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
JP2022532134A (ja) Ｏｘ４０に特異的な二環式ペプチドリガンド
JP2022513806A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
JP2022517399A (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
JP2022515720A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
JP2022515721A (ja) ＦＡＰαに特異的な二環式ペプチドリガンド
JP2023506083A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
HK40080423A (en) Bicyclic peptide ligands specific for epha2
HK40080423B (en) Bicyclic peptide ligands specific for epha2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702